Clinical and Adverse Outcomes Associated with Concomitant Use of CYP2D6-Metabolized Opioids with Antidepressants in Older Nursing Home Residents

This study aimed to investigate the associations of concomitant use of CYP2D6-metabolized opioids and antidepressants with clinical outcomes and opioid-related adverse events (ORAEs). Using a 100% Medicare NH sample, we conducted a retrospective cohort study among 80,319 NH older ( ≥65 years) long-term (> 100 days) residents who initiated CYP2D6-metabolized opioids and antidepressants concurrently or initiated one drug class while already receiving the other.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research